miR-155 drives telomere fragility in human breast cancer by targeting TRF1.
Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S.
Dinami R, et al. Among authors: ciani y.
Cancer Res. 2014 Aug 1;74(15):4145-56. doi: 10.1158/0008-5472.CAN-13-2038. Epub 2014 May 29.
Cancer Res. 2014.
PMID: 24876105